Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Anti-NKG2A Antibody

<strong>anti-NKG2A Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2014707_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8¬∞C_x000D_ <strong>Keywords:</strong> CD antigen CD159a, CD159 antigen-like family member A, CD159A;C-lectin type II protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, Corallo M, Perillo A, Scambia G, Pierelli L, Rutella S. Thymoglobulin, interferon-Œ≥ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures J Transl Med. 2010 Dec 7;8:129._x000D_ 2: Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits J Immunol. 1996 Dec 1;157(11):4741-5._x000D_ 3: Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, Zhao Y, Yin X, Guo X, Wu X, Zhang H, Xu J, Hu J, Jing J, Ma X, Shi H. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance Cancer Cell. 2023 Feb 13;41(2):272-287.e9._x000D_ 4: Salom√© B, Sfakianos JP, Ranti D, Daza J, Bieber C, Charap A, Hammer C, Banchereau R, Farkas AM, Ruan DF, Izadmehr S, Geanon D, Kelly G, de Real RM, Lee B, Beaumont KG, Shroff S, Wang YA, Wang YC, Thin TH, Garcia-Barros M, Hegewisch-Solloa E, Mace EM, Wang L, O'Donnell T, Chowell D, Fernandez-Rodriguez R, Skobe M, Taylor N, Kim-Schulze S, Sebra RP, Palmer D, Clancy-Thompson E, Hammond S, Kamphorst AO, Malmberg KJ, Marcenaro E, Romero P, Brody R, Viard M, Yuki Y, Martin M, Carrington M, Mehrazin R, Wiklund P, Mellman I, Mariathasan S, Zhu J, Galsky MD, Bhardwaj N, Horowitz A. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer Cancer Cell. 2022 Sep 12;40(9):1027-1043.e9._x000D_ 5: Andr√© P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bl√©ry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells Cell. 2018 Dec 13;175(7):1731-1743.e13._x000D_ 6: van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andr√© P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. NKG2A Blockade Potentiates CD8¬†T Cell Immunity Induced by Cancer Vaccines Cell. 2018 Dec 13;175(7):1744-1755.e15._x000D_ 7: van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andr√© P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. NKG2A Blockade Potentiates CD8¬†T Cell Immunity Induced by Cancer Vaccines Cell. 2018 Dec 13;175(7):1744-1755.e15._x000D_ 8: Borst L, van der Burg SH, van Hall T. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment Clin Cancer Res. 2020 Nov 1;26(21):5549-5556._x000D_ 9: Wang X, Xiong H, Ning Z. Implications of NKG2A in immunity and immune-mediated diseases Front Immunol. 2022 Aug 10;13:960852._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31623687">10: van Hall T, Andr√© P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. Monalizumab: inhibiting the novel immune checkpoint NKG2A J Immunother Cancer. 2019 Oct 17;7(1):263. </a>_x000D_ _x000D_ <strong>Products Related to anti-NKG2A Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>

Product Specifications

CAS Number

9007-83-4

Short Description

Catalog Number: B2014707 (10 µL)

Weight

0.15

Length

2

Width

0.5

Height

0.5

More Discoveries

Explore Other Products

Browse additional items from our catalog

Phospho-VAV3 (Y173) Antibody
A19002-100UG 100 µg

Phospho-VAV3 (Y173) Antibody

Sign In for Pricing
View Details
PTPN5 Human shRNA Plasmid Kit (Locus ID 84867)
TR310058 1 Kit

PTPN5 Human shRNA Plasmid Kit (Locus ID 84867)

Sign In for Pricing
View Details
CER1 (d18:1/28:0/18:2)
HY-N15835 1 Each

CER1 (d18:1/28:0/18:2)

Sign In for Pricing
View Details
Lentiviral human TPH2 shRNA (UAS) - Lentiviral human TPH2 shRNA (UAS, iRFP) plasmid
GTR15135700 1 Vial

Lentiviral human TPH2 shRNA (UAS) - Lentiviral human TPH2 shRNA (UAS, iRFP) plasmid

Sign In for Pricing
View Details
Recombinant Shigella boydii serotype 18 PKHD-type hydroxylase ybiX (ybiX)
MBS1207492-01 0.02 mg (E-Coli)

Recombinant Shigella boydii serotype 18 PKHD-type hydroxylase ybiX (ybiX)

Sign In for Pricing
View Details
Recombinant Shigella boydii serotype 18 PKHD-type hydroxylase ybiX (ybiX)
MBS1207492-02 0.1 mg (E-Coli)

Recombinant Shigella boydii serotype 18 PKHD-type hydroxylase ybiX (ybiX)

Sign In for Pricing
View Details